Merck related Press Releases
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
Merck Announces Top-Line Results of TRA-2P Study of VorapaxarCompany Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps WHITEHOUSE STATION, N.J., Feb 07, 2012 (BUSINESS Read more...
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known outside the United States and Canada as Read more...
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia Company Confirms Plans to File NDA for Suvorexant in 2012 Read more...
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatme
Company Confirms Plans to File NDA for Suvorexant in 2012 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on Read more...
Life Technologies Names Alan Sachs as Head of Global Research and Development
A molecular biologist and Merck veteran, Sachs will drive technology strategy and product innovationCARLSBAD, Calif., Jan. 31, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today Read more...
Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- As previously announced on Oct. 31, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its 2011 full-year and fourth-quarter Read more...
Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer Read more...
Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Read more...
Merck to Present at Goldman Sachs 2012 Healthcare Event
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer Read more...
Lycera Achieves First Milestone in Merck Research Collaboration
Partnership Focused on Developing Drugs Targeting the Th17 Pathway through the Inhibition of RORγt to Treat Autoimmune Diseases ANN ARBOR, Mich.--(BUSINESS WIRE)-- Lycera Corp., a biopharmaceutical Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
